相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
ABATACEPT SC VERSUS ADALIMUMAB ON BACKGROUND METHOTREXATE IN RA: ONE YEAR RESULTS FROM THE AMPLE STUDY
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
TOCILIZUMAB (TCZ) MONOTHERAPY IS SUPERIOR TO ADALIMUMAB (ADA) MONOTHERAPY IN REDUCING DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): 24-WEEK DATA FROM THE PHASE 4 ADACTA TRIAL
C. Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis A Randomized Trial
Marije F. Bakker et al.
ANNALS OF INTERNAL MEDICINE (2012)
Lack of Head-to-head Trials and Fair Control Arms Randomized Controlled Trials of Biologic Treatment for Rheumatoid Arthritis
Candice Estellat et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
ON THE INDEPENDENCE OF DATA MONITORING COMMITTEE IN ADAPTIVE DESIGN CLINICAL TRIALS
Shein-Chung Chow et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2012)
Incorporating biomarkers into clinical trial designs: points to consider
Edward Bradley
NATURE BIOTECHNOLOGY (2012)
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA
Josef S. Smolen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
OMERACT 10 Sharp Symposium: Important Findings in Examination of Imaging Methods for Measurement of Joint Damage in Rheumatoid Arthritis
Vibeke Strand et al.
JOURNAL OF RHEUMATOLOGY (2011)
Development and Preliminary Validation of a Magnetic Resonance Imaging Joint Space Narrowing Score for Use in Rheumatoid Arthritis: Potential Adjunct to the OMERACT RA MRI Scoring System
Mikkel Ostergaard et al.
JOURNAL OF RHEUMATOLOGY (2011)
The OMERACT Ultrasound Task Force - Status and Perspectives
Esperanza Naredo et al.
JOURNAL OF RHEUMATOLOGY (2011)
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Nicholas B. La Thangue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Gain in Popularity of Noninferiority Trial Design: Caveat Lector
Lee Vermeulen
PHARMACOTHERAPY (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3-and 6-month response rates in trials of biological agents
M. Boers
ANNALS OF THE RHEUMATIC DISEASES (2010)
A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals
Maarten Boers
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
R. Knevel et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
Cecile Gaujoux-Viala et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
J. L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs
Nicolino Ruperto et al.
ARTHRITIS AND RHEUMATISM (2010)
Viewpoints on the FDA Draft Adaptive Designs Guidance from the PhRMA Working Group
Paul Gallo et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2010)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The BeSt story: on strategy trials in rheumatoid arthritis
Naomi B. Klarenbeek et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Explanatory and Pragmatic Attitudes in Therapeutical Trials (Reprinted from J Chron Dis, vol 20, pg 637-648, 1967)
Daniel Schwartz et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
R. F. van Vollenhoven et al.
LANCET (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis
Katrina E. Donahue et al.
ANNALS OF INTERNAL MEDICINE (2008)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Effect of the Early Use of the Anti-Tumor Necrosis Factor Adalimumab on the Prevention of Job Loss in Patients With Early Rheumatoid Arthritis
Victoria Bejarano et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Edward Keystone et al.
ARTHRITIS AND RHEUMATISM (2008)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Speeding up the evaluation of new agents in cancer
Mahesh K. B. Parmar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
Paul Emery et al.
LANCET (2008)
Issues in the design of new clinical trials for rheumatoid arthritis therapeutics
William D. Schwieterman
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2008)
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
M. C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Improving the reporting of pragmatic trials: an extension of the CONSORT statement
Merrick Zwarenstein et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Early rheumatoid arthritis: strategies for prevention and management
Bernard Combe
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2007)
Making sense of noninferiority: A clinical and statistical perspective on its application to cardiovascular clinical trials
Sanjay Kaul et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2007)
Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. Is there another way?
Kevin J. Carroll
PHARMACEUTICAL STATISTICS (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2006)
Good enough: A primer on the analysis and interpretation of noninferiority trials
Sanjay Kaul et al.
ANNALS OF INTERNAL MEDICINE (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) - A randomized, controlled trial
YPM Goekoop-Ruiterman et al.
ARTHRITIS AND RHEUMATISM (2005)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis -: A longitudinal analysis
PMJ Welsing et al.
ARTHRITIS AND RHEUMATISM (2004)
Radiography as primary outcome in rheumatoid arthritis:: acceptable sample sizes for trials with 3 months' follow up
K Bruynesteyn et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2004)
Appropriate and effective management of rheumatoid arthritis
FC Breedveld et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Active-control clinical trials to establish equivalence or noninferiority: Methodological and statistical concepts linked to quality
M Gomberg-Maitland et al.
AMERICAN HEART JOURNAL (2003)
Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics
RB D'Agostino et al.
STATISTICS IN MEDICINE (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases
SS Ellenberg et al.
ANNALS OF INTERNAL MEDICINE (2000)
Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 1: Ethical and scientific issues
R Temple et al.
ANNALS OF INTERNAL MEDICINE (2000)
分享论文
